BC Innovations | Jun 8, 2018
Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
BC Innovations | May 9, 2018
Translation in Brief

The fate of NK cells

New research is elucidating the relationship between CAR-transfected NK cells’ differentiation states and their cancer-killing potential -- knowledge that Fate Therapeutics Inc. (NASDAQ:FATE) is leveraging for its own cell therapies. In a study published in...
BC Week In Review | Mar 9, 2018
Company News

BMS, Innate say no plans to table lirilumab just yet

Innate Pharma S.A. (Euronext:IPH) confirmed that discussions with partner Bristol-Myers Squibb Co. (NYSE:BMY) remain ongoing regarding next steps for cancer compound lirilumab (BMS-986015, IPH2102). In November, Innate said efficacy data from a Phase I/II trial...
BC Week In Review | Dec 1, 2017
Clinical News

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to...
BioCentury | Apr 7, 2017

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
BC Week In Review | Feb 10, 2017
Clinical News

Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in first complete remission showed that maintenance treatment with 0.1 mg/kg lirilumab every 3 months and 1 mg/kg lirilumab...
BC Extra | Feb 6, 2017
Clinical News

Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab ( IPH2102 ) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with acute myelogenous...
BC Week In Review | Jan 12, 2017
Company News

Innate Pharma, Bristol-Myers deal

Innate received a $15 million milestone payment from Bristol-Myers under a 2011 deal granting BMS exclusive, worldwide rights to lirilumab, a human mAb against killer cell immunoglobulin-like receptors (KIR). Innate said the milestone was triggered...
BC Week In Review | Nov 11, 2016
Clinical News

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-001 trial showed that IV lirilumab every 4...
BC Extra | Nov 9, 2016
Clinical News

Lirilumab combo shows early promise in SCCHN

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from a Phase I/II trial of lirilumab ( IPH2102 ) plus PD-1 inhibitor Opdivo nivolumab that suggest the combination may offer a clinical benefit in patients with advanced platinum-refractory squamous...
Items per page:
1 - 10 of 38